The Effect of Semaglutide on Pituitary Function

University of Tartu10 enrolled

Overview

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

The randomized blinded placebo-controlled clinical trial is conducted on 10 healthy volunteers. 5 study subjects receive once 7 mg of oral semaglutide and once placebo. 5 study subjects receive once 14 mg of oral semaglutide and once placebo. The study group and order of administration of study medication are decided on randomization. The placebo and oral semaglutide are administered at least 4 weeks apart. Blood samples are taken before and during 4 hours after the study medication administration (at 60, 90, 120, 150, 180, and 240 minutes after study medication administration). The primary endpoint is the peak value of growth hormone measured during the 4 hours after study medication administration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

Semaglutide 7 MG Oral TabletDRUG

Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.

PlaceboDRUG

Placebo tablet is taken after an overnight fast with up to120 ml of water.

Semaglutide 14 MG Oral TabletDRUG

Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-50 years * The body weight \>65 kg Exclusion Criteria: * presence of chronic illness * the daily use of medications * pregnancy * lactation.

Locations (1)

Tartu University Hospital

Tartu, Estonia